Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 2;10(11):2469.
doi: 10.3390/jcm10112469.

Aspergillus in Critically Ill COVID-19 Patients: A Scoping Review

Erlangga Yusuf  1 , Leonard Seghers  2 , Rogier A S Hoek  2 , Johannes P C van den Akker  3 , Lonneke G M Bode  1 , Bart J A Rijnders  1   4
Affiliations

Aspergillus in Critically Ill COVID-19 Patients: A Scoping Review

Erlangga Yusuf et al. J Clin Med. .

Abstract

Several reports have been published on Aspergillus findings in COVID-19 patients leading to a proposition of new disease entity COVID-19-associated pulmonary aspergillosis. This scoping review is designed at clarifying the concepts on how the findings of Aspergillus spp. in COVID-19 patients were interpreted. We searched Medline to identify the studies on Aspergillus spp. findings in COVID-19 patients. Included were observational studies containing the following information: explicit mention of the total number of the study population, study period, reason for obtaining respiratory samples, case definition, and clinical outcomes. Excluded were case series, case reports and reviews. Identified were 123 publications, and 8 observational studies were included. From the included studies the following issues were identified. The proportion of immunocompromised patients considered as host factors varied from 0 to 17%. Most of the studies did not mention radiographic findings explicitly. Respiratory samples were mostly obtained to investigate clinical deterioration. Aspergillus culture, antigen or PCR testing on bronchoalveolar lavage (BAL) fluid were performed in between 23.3% and 66.3% of the study population. Two studies performed periodic samples of BAL. Galactomannan index (GI) positivity in BAL was between 10% and 28%. GI in blood was found in 0.9% to 6.7% of the available samples. The prevalence of COVID-19-associated pulmonary aspergillosis ranged from 2.7% to 27.7%. Studies compared the mortality between defined cases and non-cases, and all showed increased mortality in cases. No studies showed that antifungal treatment reduced mortality. Concluding, this review showed how studies defined the clinical entity COVID-19-associated pulmonary aspergillosis where positive Aspergillus test in the respiratory sample was the main driver for the diagnosis. There were many differences between studies in terms of test algorithm and Aspergillus test used that largely determined the prevalence. Whether antifungal therapy, either as prophylaxis, pre-emptive or targeted therapy will lead to better outcomes of COVID-19-associated pulmonary aspergillosis patients is still need to be answered.

Keywords: Aspergillus; COVID-19; mortality; scoping review.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Literature flow.
See this image and copyright information in PMC

References

    1. Lin S.J., Schranz J., Teutsch S.M. Aspergillosis case-fatality rate: Systematic review of the literature. Clin. Infect. Dis. 2001;32:358–366. doi: 10.1086/318483. - DOI - PubMed
    1. Vanderbeke L., Spriet I., Rijnders B.J.A., Verweij P.E., Wauters J. Invasive pulmonary aspergillosis complicating severe influenza: Epidemiology, diagnosis and treatment. Curr. Opin. Infect. Dis. 2018;31:471–480. doi: 10.1097/QCO.0000000000000504. - DOI - PubMed
    1. Lai C.C., Yu W.L. COVID-19 associated with pulmonary aspergillosis: A literature review. J. Microbiol. Immunol. Infect. 2021;54:46–53. doi: 10.1016/j.jmii.2020.09.004. - DOI - PMC - PubMed
    1. Apostolopoulou A., Garrigos Z.E., Vijayvargiya P., Lerner A.H., Farmakiotis D. Invasive pulmonary aspergillosis in patients with SARS-CoV-2 infection: A systematic review of the literature. Diagnostics. 2020;10:807. doi: 10.3390/diagnostics10100807. - DOI - PMC - PubMed
    1. Munn Z., Peters M.D.J., Stern C., Tufanaru C., McArthur A., Aromataris E. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med. Res. Methodol. 2018;18:1–7. doi: 10.1186/s12874-018-0611-x. - DOI - PMC - PubMed

Publication types

LinkOut - more resources